MX2021015439A - Moleculas multivalentes de union a fzd y wnt y usos de las mismas. - Google Patents

Moleculas multivalentes de union a fzd y wnt y usos de las mismas.

Info

Publication number
MX2021015439A
MX2021015439A MX2021015439A MX2021015439A MX2021015439A MX 2021015439 A MX2021015439 A MX 2021015439A MX 2021015439 A MX2021015439 A MX 2021015439A MX 2021015439 A MX2021015439 A MX 2021015439A MX 2021015439 A MX2021015439 A MX 2021015439A
Authority
MX
Mexico
Prior art keywords
fzd
multivalent
receptor
binding molecules
wnt
Prior art date
Application number
MX2021015439A
Other languages
English (en)
Inventor
Stephane Angers
Sachdev Sidhu
Yuyong Tao
Original Assignee
Antlera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antlera Therapeutics Inc filed Critical Antlera Therapeutics Inc
Publication of MX2021015439A publication Critical patent/MX2021015439A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

En el presente documento se describen métodos para afectar la unión de una molécula de unión multivalente a un receptor de FZD y un correceptor de Wnt en una célula, en donde la unión de la molécula de unión multivalente tanto al receptor como al correceptor de FZD en la célula, activa una vía de señalización de Wnt. También se describen en el presente documento moléculas de unión multivalentes que comprenden un dominio de unión al receptor de FZD y un dominio de unión al correceptor de Wnt en cualquiera de los extremos de un dominio Fc que activan una vía de señalización de Wnt y métodos para su uso.
MX2021015439A 2019-06-11 2020-06-10 Moleculas multivalentes de union a fzd y wnt y usos de las mismas. MX2021015439A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962860161P 2019-06-11 2019-06-11
PCT/IB2020/055463 WO2020250156A1 (en) 2019-06-11 2020-06-10 Multivalent fzd and wnt binding molecules and uses thereof

Publications (1)

Publication Number Publication Date
MX2021015439A true MX2021015439A (es) 2022-03-11

Family

ID=73782094

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015439A MX2021015439A (es) 2019-06-11 2020-06-10 Moleculas multivalentes de union a fzd y wnt y usos de las mismas.

Country Status (11)

Country Link
US (1) US20220315659A1 (es)
EP (1) EP3983443A4 (es)
JP (1) JP7377288B2 (es)
KR (1) KR20220024460A (es)
CN (1) CN114423784A (es)
AU (1) AU2020291208A1 (es)
BR (1) BR112021024787A2 (es)
CA (1) CA3140580A1 (es)
IL (1) IL288730A (es)
MX (1) MX2021015439A (es)
WO (1) WO2020250156A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574019A4 (en) 2017-01-26 2021-03-03 Surrozen, Inc. TISSUE SPECIFIC, WNT SIGNAL REINFORCEMENT MOLECULES AND USES THEREOF
WO2022130342A1 (en) * 2020-12-18 2022-06-23 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067986B2 (en) * 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
RU2630637C2 (ru) * 2011-08-05 2017-09-11 Дженентек, Инк. Анти-полиубиквитиновые антитела и способы применения
US10077304B2 (en) * 2013-08-14 2018-09-18 The Governing Council Of The University Of Toronto Antibodies against frizzled receptor
JP6796059B2 (ja) 2014-09-12 2020-12-02 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｗｎｔシグナリングアゴニスト分子
EP3574019A4 (en) * 2017-01-26 2021-03-03 Surrozen, Inc. TISSUE SPECIFIC, WNT SIGNAL REINFORCEMENT MOLECULES AND USES THEREOF
CN111727203B (zh) * 2017-12-19 2024-04-26 瑟罗泽恩奥普瑞汀公司 Wnt替代分子和其用途
CA3129736A1 (en) * 2018-02-14 2019-08-22 Antlera Therapeutics Inc. Multivalent binding molecules activating wnt signaling and uses thereof

Also Published As

Publication number Publication date
KR20220024460A (ko) 2022-03-03
JP2022536142A (ja) 2022-08-12
EP3983443A4 (en) 2023-06-07
BR112021024787A2 (pt) 2022-05-03
JP7377288B2 (ja) 2023-11-09
CA3140580A1 (en) 2020-12-17
US20220315659A1 (en) 2022-10-06
CN114423784A (zh) 2022-04-29
EP3983443A1 (en) 2022-04-20
IL288730A (en) 2022-02-01
AU2020291208A1 (en) 2022-01-06
WO2020250156A1 (en) 2020-12-17

Similar Documents

Publication Publication Date Title
MX2023006482A (es) Anticuerpos biespecificos especificos para un receptor de tnf coestimulador.
AR106574A1 (es) Anticuerpos biespecíficos con tetravalencia para un receptor de fnt coestimulador
EA201890866A1 (ru) Связывающие молекулы, которые ингибируют рост рака
EP3870223A4 (en) MULTIVALENT IGM AND IGA-FC BASED BINDING MOLECULES
ECSP17083779A (es) Agentes de unión a inmunorreceptor de células t con dominios ig y motivo de inhibición basado en tirosina de inmunorreceptor (tigit) y usos de los mismos
GEP20227398B (en) Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
MX2021015439A (es) Moleculas multivalentes de union a fzd y wnt y usos de las mismas.
CL2017000954A1 (es) Moléculas de unión a antígeno biespecificas activadoras de células t
MX2020006409A (es) Moléculas de unión al antígeno específicas para ror1.
BR112017011932A8 (pt) Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
BR112018013677A2 (pt) proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
ZA202006644B (en) Hydrocarbon mixture exhibiting unique branching structure
WO2016040895A8 (en) Wnt signaling agonist molecules
ECSP13013022A (es) Agonistas de fgfr1 y sus métodos de uso
CL2009001258A1 (es) Polipeptido multivalente que comprende dos dominios de fibronectina tipo iii, ligados por un polipeptido de engarce basado en glicina-serina o glicina-prolina.
EA201170030A1 (ru) Il-6-опосредованная иммунотерапия
EP3752537A4 (en) WNT SIGNALING ACTIVATING MULTIVALENT BINDING MOLECULES AND THEIR USES
BR112017013111A2 (pt) métodos de tratamento de um distúrbio e de tratamento da sinovite, uso de um anticorpo e anticorpo
EA201790314A1 (ru) Новые антитела, направленные на fc-гамма-рецептор iib и fc-эпсилон-рецептор
BR112018000584A2 (pt) proteínas de fusão com ligação de dr5 multivalentes e multiespecíficas
WO2009043355A3 (en) SYSTEMIC PRO-HEMOSTATIC EFFECT OF SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH
EA201991852A1 (ru) Модуляторы печеночного х рецептора (lxr)
BR112019003712A2 (pt) composições marcadoras, e métodos para produção e uso das mesmas
CL2023001768A1 (es) Moléculas de anticuerpos de unión tetravalentes y usos de las mismas
BR112015028082A2 (pt) ensaio de internalização de receptor de sabor